Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399908 | 0.93 | MAPK14 (0.47) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL1399846 | 0.90 | MAPK14 (0.45) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL1399730 | 0.88 | MAPK14 (0.49) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL1004406 | 0.87 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL1399915 | 0.86 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL1399829 | 0.85 | MAPK14 (0.52) | MAPK14CYP3A4 | |
| SCHEMBL1400011 | 0.85 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL1399911 | 0.84 | MAPK14 (0.51) | MAPK14CYP3A4 | |
| SCHEMBL1399966 | 0.80 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL1140810 | 0.80 | MAPK14 (0.59) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831174-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | claimed |
| US-7786115-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-08-31 | — | — | US | claimed |
| US-20080146566-A1 | Amide Derivatives | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| EP-1831174-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067444-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| EP-1831174-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7786115-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-08-31 | — | — | US | disclosed |
| US-20080146566-A1 | Amide Derivatives | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146566-A1 | Amide Derivatives | IL6, IL1B, IL1A | MAPK14 2077/4885CYP3A4 234/4885CYP2C9 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.